Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Prophylaxis for Campylobacteriosis
NCT02280044Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in campylobacteriosis, sponsored by Johns Hopkins Bloomberg School of Public Health. Started Oct 2014; status: completed.
02
Drugs
rifaximin
03
Conditions
campylobacteriosis
Beyond the preview
Go deeper on NCT02280044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280044.